Update on Therapeutic Drug Monitoring in Crohn's Disease

被引：11
作者：
Heron, Valerie [1 ]
Afif, Waqqas [1 ]
机构：
[1] McGill Univ, Montreal Gen Hosp, Hlth Ctr, Div Gastroenterol, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada
来源：
GASTROENTEROLOGY CLINICS OF NORTH AMERICA | 2017年 / 46卷 / 03期
关键词：
Therapeutic drug monitoring; Biologics; Anti-tumor necrosis factor; Drug concentrations; Anti-drug antibodies; Crohn's disease; Inflammatory bowel disease; INFLAMMATORY-BOWEL-DISEASE; INFLIXIMAB TROUGH LEVELS; ADALIMUMAB DRUG; ANTIBODY CONCENTRATIONS; ANTIDRUG ANTIBODIES; MAINTENANCE THERAPY; CLINICAL-RESPONSE; RANDOMIZED-TRIAL; DOSE-ESCALATION; REMISSION;
D O I：
10.1016/j.gtc.2017.05.014
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
In patients with Crohn's disease on biologic medications, the use of therapeutic drug monitoring leads to a personalized approach to optimize treatment. Using an algorithmic approach, measurement of drug concentrations and anti-drug antibodies can be used to improve treatment outcomes. Therapeutic drug concentrations and absence of antibodies are associated with improved clinical and endoscopic outcomes. In clinical practice, therapeutic drug monitoring has been shown to be clinically useful and cost-effective in patients experiencing a loss of response to treatment. This review highlights the available data on therapeutic drug monitoring in the treatment of patients with Crohn's disease on biologic medications.
引用
收藏
页码：645 / +
页数：16
相关论文
共 72 条
  • [1] Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
    Afif, Waqqas
    Loftus, Edward V., Jr.
    Faubion, William A.
    Kane, Sunanda V.
    Bruining, David H.
    Hanson, Karen A.
    Sandborn, William J.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (05) : 1133 - 1139
  • [2] Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease
    Ainsworth, Mark A.
    Bendtzen, Klaus
    Brynskov, Jorn
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (04) : 944 - 948
  • [3] Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
    Baert, F
    Noman, M
    Vermeire, S
    Van Assche, G
    D'Haens, G
    Carbonez, A
    Rutgeerts, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) : 601 - 608
  • [4] Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial
    Baert, Filip
    Kondragunta, Venkateswarlu
    Lockton, Steven
    Casteele, Niels Vande
    Hauenstein, Scott
    Singh, Sharat
    Karmiris, Konstantinos
    Ferrante, Marc
    Gils, Ann
    Vermeire, Severine
    [J]. GUT, 2016, 65 (07) : 1126 - 1131
  • [5] Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy
    Baert, Filip
    Drobne, David
    Gils, Ann
    Vande Casteele, Niels
    Hauenstein, Scott
    Singh, Sharat
    Lockton, Steve
    Rutgeerts, Paul
    Vermeire, Severine
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (09) : 1474 - U352
  • [6] Battat R, 2017, CLIN GASTROENTEROL H
  • [7] Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawal
    Ben-Horin, S.
    Chowers, Y.
    Ungar, B.
    Kopylov, U.
    Loebstein, R.
    Weiss, B.
    Eliakim, R.
    Del Tedesco, E.
    Paul, S.
    Roblin, X.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (03) : 356 - 364
  • [8] The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD
    Ben-Horin, S.
    Mazor, Y.
    Yanai, H.
    Ron, Y.
    Kopylov, U.
    Yavzori, M.
    Picard, O.
    Fudim, E.
    Maor, Y.
    Lahat, A.
    Coscas, D.
    Eliakim, R.
    Dotan, I.
    Chowers, Y.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (06) : 714 - 722
  • [9] Review article: loss of response to anti-TNF treatments in Crohn's disease
    Ben-Horin, S.
    Chowers, Y.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (09) : 987 - 995
  • [10] Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation
    Ben-Horin, Shomron
    Vande Casteele, Niels
    Schreiber, Stefan
    Lakatos, Peter Laszlo
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (12) : 1685 - 1696
12345678